MEDEON BIODESIGN INC Inactive Instrument
Medeon Biodesign Inc Stock Taipei Exchange
Equities
Advanced Medical Equipment & Technology
|
End-of-day quote
Other stock markets
|
||
| - | - |
|
| Sales 2022 | 298M 9.21M 0 | Sales 2023 | 196M 6.06M 0 | Capitalization | 4.29B 133M 0 |
|---|---|---|---|---|---|
| Net income 2022 | -434M -13.4M - | Net income 2023 | -1.2B -37.21M - | EV / Sales 2022 | 12.5 x |
| Net cash position 2022 | 1.35B 41.64M 0 | Net cash position 2023 | 1.96B 60.38M 0 | EV / Sales 2023 | 11.9 x |
| P/E ratio 2022 |
-11.7
x | P/E ratio 2023 |
-3.56
x | Employees | - |
| Yield 2022 |
0.86% | Yield 2023 |
-
| Free-Float | 47.68% |
More Fundamentals
* Assessed data
More news
| Managers | Title | Age | Since |
|---|---|---|---|
Yu Te Chang
CEO | Chief Executive Officer | - | 12-12-21 |
Ching Yi Chen
DFI | Director of Finance/CFO | - | - |
Greta Chang
PRN | Corporate Officer/Principal | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yu Te Chang
CEO | Chief Executive Officer | - | 12-12-21 |
Chih Lung Shen
BRD | Director/Board Member | 59 | 15-04-19 |
Hong Jen Chang
BRD | Director/Board Member | 68 | 14-01-13 |
Medeon Biodesign, Inc. is a Taiwan-based company principally engaged in the research, development, manufacture and sales of medical equipment. The Company's main products include medical apparatus and instruments used in laparoscopic minimally invasive surgeries and cardiac catheter-related minimally invasive surgeries. The Company distributes its products in domestic market and to overseas markets.
Calendar
2024-08-04
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +2.24% | 205B | |
| +6.45% | 179B | |
| +31.46% | 158B | |
| +33.00% | 113B | |
| +4.87% | 64.93B | |
| +21.77% | 56.51B | |
| -2.92% | 46.36B | |
| -5.91% | 37.07B | |
| +3.39% | 36.12B |
